# Cogent Biosciences (COGT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/COGT
## Company Profile
- Ticker: COGT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 38.98 USD
- Market cap: 5597635811.04 USD
- Last updated: 2026-08-12
## Business Overview
### Genetically Defined Diseases
Cogent Biosciences develops precision therapies for diseases driven by defined oncogenic mutations. Its portfolio is led by a selective KIT inhibitor and includes earlier programs directed at ErbB2, PI3Kα, KRAS and JAK2.
### Bezuclastinib
Bezuclastinib is designed to inhibit KIT D816V and other exon 17 KIT mutations while limiting off-target activity. These mutations drive systemic mastocytosis and are also important resistance mechanisms in gastrointestinal stromal tumors.
### Systemic Mastocytosis Franchise
The company is pursuing bezuclastinib in both non-advanced and advanced systemic mastocytosis. An NDA for non-advanced disease is under FDA review, while the APEX program supports a separate planned application in advanced disease.
### Gastrointestinal Stromal Tumors
The Phase 3 PEAK trial supports an NDA for bezuclastinib in GIST after prior imatinib treatment. Cogent also plans to study bezuclastinib with sunitinib in first-line exon 9-mutant GIST, potentially extending use into an earlier treatment setting.
### Early Precision-Oncology Pipeline
CGT4255 is a brain-penetrant ErbB2 inhibitor and CGT6297 is a selective PI3Kα inhibitor, both in Phase 1 studies. Preclinical candidates CGT1815 and CGT1145 target pan-KRAS(ON) and JAK2 V617F, respectively.
## Why The Stock Is Moving

As of Aug 12, 2026, COGT closed up 0.72% at $38.98. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA action on the bezuclastinib NDA for gastrointestinal stromal tumors by the November 30, 2026 PDUFA date.
- FDA action on the bezuclastinib NDA for non-advanced systemic mastocytosis by the December 30, 2026 PDUFA date.
- Preliminary results from the SUMMIT avapritinib-switch extension trial by year-end 2026.

## Recent News
- 2026-08-10 12:00 EST — [Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2026-fi-3bc3208d) — Source: Cogent Biosciences
- 2026-06-30 12:00 EST — [Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-submission-of-new-drug-application-nda-for-bezuclas-2951df92) — Source: Cogent Biosciences
- 2026-06-12 12:01 EST — [Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-preclinical-data-from-novel-jak2-v617f-inhibitor-at-915c4be5) — Source: Cogent Biosciences
- 2026-06-12 12:00 EST — [Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-detailed-data-from-apex-pivotal-trial-of-bezuclasti-cffdc7b4) — Source: Cogent Biosciences
- 2026-05-30 12:00 EST — [Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-detailed-clinical-data-from-peak-phase-3-trial-with-bezuclastinib-in-combination-with-sunitinib-in-gastrointestinal-stromal-tumors-gist-at-2026-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Cogent Biosciences